Filed: August 25, Date of Patent: May 1, Publication date: December 30, In one embodiment, the ocular device serves as an ocular drug delivery system and contains an active pharmaceutical agent, a lubricant, etc. In a second embodiment the ocular device can be constructed in such a manner to treat a wide variety of ocular conditions and diseases.
Filed: March 12, Publication date: September 16, Abstract: Polymeric compositions containing a high percentage of bound alkyl ether segments provide matrices and membranes for the controlled release of drugs and medicinal agents. The polymeric compositions are prepared by the polymerization of ethylenically unsaturated alkyl ether containing monomers. Copolymers of ethylenically unsaturated alkyl ether containing monomers with co-monomers are also disclosed. The drug loaded polymeric compositions of this invention find particular utility in the construction of controlled release devices.
Filed: December 8, Publication date: July 15, Inventors: Jeanne Y. Ellis, Edward J. Mucin containing ophthalmic preparation. Abstract: Aqueous ophthalmic preparations are provided and are intended to be instilled into the eye, or in which to pre soak or store an object to be inserted into the eye, such as a contact lens, an ointment, or a solid device to be inserted into the conjunctival sac.
The preparations disclosed are utilized for the treatment of a tear film and ocular surface disorder known as keratoconjunctivitis sicca or dry eye syndrome. In general, the preparations of this invention are also effective for the relief of symptoms of eye irritation, such as those caused by dry environmental conditions or by contact lens wear.
In accordance with the present invention, the ophthalmic preparation includes a mucin component, similar to that found at the normal human ocular surface and in one exemplary and preferred embodiment, the mucin is a transmembrane or surface mucin.
Filed: June 22, Date of Patent: August 6, Mucin containing ophthalmic preparations. Abstract: The present invention discloses the ophthalmic applications of mucin derived from mammalian milk or milk byproducts.
This mucin has been found to be a MUC1 type mucin similar to the transmembrane mucin expressed on the surface of the human eye. The mucin-containing preparations described in this invention can be in the form of an aqueous formulation to be instilled into the eye, or in which to pre-soak or store an object to be inserted into the eye, such as a contact lens, an ointment, or a solid device to be inserted into the conjunctival sac.
The preparations disclosed are utilized for the treatment of tear film and ocular surface disorders associated with the signs and symptoms of dry eye. Furthermore, mucin-based formulations are also effective for the relief of symptoms of eye irritation, such as those caused by environmental conditions or by contact lens wear.
Filed: March 1, Date of Patent: August 28, Justia Legal Resources. Find a Lawyer. Law Students. US Federal Law. US State Law. Other Databases. It has since focussed on novel therapies for specific ocular diseases and have pursued two primary development avenues: new therapeutic agents and new drug delivery technology. Its belief is that innovative research provides technology platforms, which serve as the foundation for new product development. The members of Vista, along with their advisors and consultants are recognized experts in their fields and have a successful track record in bringing products to market, particularly in the ophthalmic field.
Although its expertise lies in the front end of product development, it is experienced in working as part of a team in bringing a product through FDA approval. Vista is located in an industrial complex within the greater Boston area. The facilities include both office and laboratory space. Their specialized laboratory is equipped to produce prototype ophthalmic solutions and devices for research evaluation.
Edward Ellis — Dr. Ellis has extensive experience in the research and development of contact lens materials and care systems. As a result of his years in the contact lens field, Dr. Ellis has gained extensive experience in water soluble polymer systems, surfactant technology, hydrogel chemistry, acrylate monomers, siloxane chemistry, fluorine-containing monomers, polymerization processes and material science.
In addition, Dr. Ellis provided technical insight to the defining of the structure-property relationships that result in improved biocompatibility of contact lenses. Charles Leahy, O. Leahy is an optometrist with a degree in post-graduate research from the department of Physiological Optics at the University of California at Berkeley. His publications and presentations on the subjects of ophthalmic devices and tear film emphasize the effects of biocompatible devices on the physiology of the eye.
0コメント